Prokarium and Probiomed today announced the start of their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks. The first vaccine to be manufactured will be developed to prevent so-called ‘Montezuma’s revenge’ or diarrhoea, which affects the local population as well travellers in Mexico and many countries.
Wed, 04/01/2017 - 07:00
Wed, 07/12/2016 - 07:30
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to expand the research collaboration with Adverum Biotechnologies that began in December 2015.
Mon, 24/10/2016 - 09:00
NALIA Systems, a developer of novel multiplex immunodiagnostic systems for clinical and research applications, announces the expansion of its board following the recent successful £500,000 fund raising.
Tue, 18/10/2016 - 14:45
London, UK, 18th October 2016 / Sciad Newswire / NALIA Systems, a developer of novel multiplex immunodiagnostic systems for clinical and research applications, ha
Tue, 04/10/2016 - 09:00
San Francisco, USA, 4th October 2016 / Sciad Newswire / Biologist and inventor of new transposase-based tool, Kate Caves discusses DNA2.0’s emerging cell engineer
Tue, 27/09/2016 - 09:00
Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from Mercia Technologies PLC.
Wed, 21/09/2016 - 14:00
Probiomic Therapeutics™ for Eczema, Atopic Dermatitis, Eosinophilic Esophagitis (EoE), Metabolic Disorders
Wed, 22/06/2016 - 08:30
Results reveal key differences between digital health and other life science companies.
Thu, 05/05/2016 - 09:00
Mercia has committed follow-on capital to Medherant Ltd. Medherant’s patch, known as the TEPI-patch®, is a thin, strong, easy-to-apply and easy-to-remove patch capable of delivering higher doses of drugs.
Wed, 20/01/2016 - 13:00
BÜHLMANN Laboratories is proud to announce the availability of its products directly from its new North American affiliate, BUHLMANN Diagnostics Corp (BDC) in Southern New Hampshire.